Epithalon: The Russian Telomere Peptide With 40 Years of Clinical Use

Most peptides in the longevity space emerged from Western pharmaceutical research in the past 10 to 20 years. Epithalon is an exception. It was developed in Saint Petersburg by Vladimir Khavinson at the Institute of Bioregulation and Gerontology, building on the work of Professor Vladimir Dilman from the 1960s. Epithalon has been in use in Russian clinical medicine since the 1980s and registered as a pharmaceutical product in Russia for decades.

Epithalon is a short tetrapeptide with the sequence Ala-Glu-Asp-Gly, designed to restore the signalling function of the pineal gland — the small endocrine structure at the centre of the brain responsible for melatonin production and circadian rhythm regulation. It is the synthetic version of a larger pineal extract called Epithalamin, which was the product originally used in Dilman's pioneering clinical studies.

The Khavinson group has published over 200 papers on peptide bioregulators across multiple journals, and the approach is a mainstream part of Russian clinical gerontology. It has received much less attention in Western medicine, partly because the theoretical framework (short-peptide gene regulation) sits outside conventional Western pharmacology.

The study most cited in support of Epithalon is a prospective clinical trial run by Vladimir Anisimov and Vladimir Khavinson over 15 years, from 1992 to 2007. It enrolled 266 elderly patients aged 60 to 92 at baseline. Participants were randomised to three groups: control, Epithalamin (pineal extract) alone, or Epithalamin plus Thymalin (a thymic peptide complex).

The trial reported a 28 percent reduction in all-cause mortality in the peptide-treated groups compared to controls over the follow-up period. Cancer incidence and cardiovascular events were also reported as reduced. This is an unusually long trial by any standard, and the reported effect size is large.

Two important caveats are needed when reading this result. First, the trial predates the current standards of randomised controlled trial methodology and pre-registration. Second, it has not been replicated by any Western research group. Third, the Epithalamin used in the trial is the larger pineal extract rather than the synthetic Ala-Glu-Asp-Gly tetrapeptide that is sold commercially today, though Khavinson's group has argued the tetrapeptide captures the active component.

For a Western evidence-based audience, the trial is best understood as a strong observational signal from a serious research group with decades of clinical involvement, rather than as definitive proof of efficacy.

The claim that has driven most of the English-language interest in Epithalon is the idea that it activates telomerase — the enzyme that extends telomeres at the ends of chromosomes. Telomere shortening is one of the 12 hallmarks of aging, and any compound that reliably activates telomerase in somatic cells would be genuinely novel.

The original data for this claim comes from Khavinson's group, who reported in 2003 that Epithalon increased telomerase activity in cultured human somatic cells by approximately 2 to 3 fold and extended telomere length over multiple cell divisions. Subsequent Russian studies have reported similar findings in various tissue types.

Western replication of this specific telomerase-activating effect has been limited. A handful of independent in-vitro studies have examined Epithalon's effects on aging biomarkers and confirmed some gene-expression changes, but the specific telomerase-activation claim has not been rigorously reproduced outside the Khavinson group.

This is important because many marketing claims about Epithalon in the English-language biohacking community extrapolate from 'increased telomerase activity in cultured cells' to 'slows aging in humans' without intermediate evidence. The in-vitro data is suggestive. The in-vivo clinical evidence for telomere lengthening in humans is not established.

The mechanism proposed by Khavinson's group is part of a broader theory of peptide bioregulation. Short peptides, the theory goes, can penetrate the cell nucleus and interact directly with specific sequences of DNA to influence gene expression in target tissues. In pinealocytes (the cells of the pineal gland), Epithalon is proposed to upregulate genes involved in melatonin synthesis (particularly AANAT and ASMT), restoring the age-associated decline in pineal function.

This is a different conceptual framework from most Western pharmacology, which focuses on receptor binding and downstream signalling cascades. The bioregulation theory postulates something closer to an epigenetic intervention — short peptides as direct modulators of gene expression.

Western researchers have generally been sceptical of the strong form of this theory. What is better established is that Epithalon can restore elements of pineal function in animal models: melatonin secretion patterns, circadian rhythm amplitude, and antioxidant enzyme expression. Whether this represents direct DNA binding, receptor-mediated signalling, or some other mechanism is still not fully resolved in the Western literature.

The protocols used in Russian clinical practice for Epithalon typically involve short cycles rather than continuous dosing. A common protocol is 5 to 10 mg per day by intramuscular or subcutaneous injection for 10 days, repeated 2 to 3 times per year. This reflects the bioregulator concept of triggering a reset of gene expression rather than providing ongoing supplementation.

Oral formulations are also used, at higher doses (typically 20 to 50 mg) to compensate for lower bioavailability. The oral form is often sold as 'Epitalon' capsules through Russian pharmaceutical channels.

Community protocols in the English-language biohacking space often follow similar short-cycle dosing but vary widely. Some users describe daily 10 mg subcutaneous for 10 to 20 days, repeated yearly. Others describe more continuous protocols. There is no consensus optimal dose from clinical trial data.

The short-cycle approach has a theoretical virtue: if the goal is to trigger changes in gene expression rather than maintain plasma levels, pulsatile dosing makes mechanistic sense. Whether this matters in practice has not been rigorously tested.

Epithalon has a long history of clinical use in Russia with no major safety signals reported. The Khavinson group's published data covers over 30 years of clinical experience in several thousand patients, and no serious adverse events have been attributed to the peptide.

Commonly reported effects are mild: injection site reactions, occasional headache, vivid dreams (consistent with pineal activation), and improved sleep quality. No drug interactions of clinical significance have been identified, though formal interaction studies are limited.

As with other research peptides, material available through non-pharmaceutical channels has not been manufactured to the same standards as the Russian pharmaceutical product. Purity, sterility, and endotoxin levels can vary substantially between suppliers.

For readers building a longevity protocol, Epithalon occupies a specific niche: it targets the pineal–circadian axis, which is increasingly recognised as a central node in aging biology.

The pineal gland shrinks and calcifies progressively with age. Melatonin secretion drops by 80 percent between early adulthood and old age. Circadian rhythm amplitude flattens. These changes are associated with increased mortality, cognitive decline, and cancer risk in large observational studies. Epithalon is one of the few interventions specifically proposed to target this system mechanistically.

Compared to other longevity peptides, Epithalon is closer to the Khavinson-tradition bioregulators (Pinealon, Thymalin, Cortexin) than to the Western-developed peptides (SS-31, MOTS-c). The evidence base is older, more clinical, and less mechanistically mainstream. The clinical trial data is stronger than most biohacking compounds but has not been replicated by Western research groups.

Anyone considering Epithalon as part of a protocol should understand that they are essentially trusting the Khavinson-group research programme. That research is extensive and serious, but it is not the same as having a Western phase-3 clinical trial to point to.

For the full Epithalon peptide profile including detailed dosing and mechanism information, see /peptides/epithalon.

For a companion peptide from the same Russian tradition that works on sleep and neuroprotection, see the Pinealon entry at /peptides/pinealon.

For the Western mitochondrial peptides in active clinical development, see our SS-31 guide at /guides/ss-31-elamipretide-mitochondrial-peptide and MOTS-c guide at /guides/mots-c-exercise-mimetic-peptide.

For vendors that stock Epithalon in Australia and the UK, see /vendors.

This guide is for educational purposes only and does not constitute medical advice. Epithalon is not registered on the Australian Register of Therapeutic Goods and is not approved as a therapeutic in Australia, the US, or most Western jurisdictions. It is classified as a Schedule 4 compound when intended for therapeutic use. Any research or investigational use should be discussed with a qualified healthcare professional. Claims about telomerase activation or lifespan extension in humans are not established by clinical trial evidence.